跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
YKL-40
首页
药物
YKL-40
YKL-40
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
YKL-40 monoclonal antibody
US 8053563 B2
申请人: BIO Y AS
优先权: 2005
US
4 件公开
IRNA COMPOSITIONS AND METHODS FOR SILENCING CHITINASE 3-LIKE PROTEIN 1/YKL-40 (CHI3L1/YKL-40) PROTEIN
EP 4326877 A4
申请人: ALNYLAM PHARMACEUTICALS INC
优先权: 2021
EP
US
WO
3 件公开
Cancer antigen peptide and the use thereof
US 7902143 B2
申请人: TORAY INDUSTRIES
优先权: 2004
CN
US
3 件公开
Cosmetic use of chitinase-type proteins
US 9926587 B2
申请人: BERNARD DOMINIQUE
优先权: 2006
CN
US
3 件公开
YKL-40 as a marker for gastrointestinal cancers
US 8580520 B2
申请人: JOHANSEN JULIA SIDENIUS
优先权: 2008
CN
US
3 件公开
Anti-chitinase-3-like protein-1 (YKL-40) neutralizing antibody and uses thereof
US 12692324 B2
申请人: INST OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL EXECUTIVE YUAN R O C
优先权: 2022
US
3 件公开
YKL-40-targeting human monoclonal antibody
US 12534520 B2
申请人: SENELIX CO LTD
优先权: 2019
CN
US
2 件公开
ANTIBODIES AGAINST YKL-40 AND USES THEREOF
EP 4702056 A1
申请人: BIO Y AS
优先权: 2023
EP
WO
2 件公开
US 12428495 B2
申请人: BIO Y AS
优先权: 2023
US
Assay for YKL-40 as a marker for degradation of mammalian connective tissue matrices
US 7230086 B2
申请人: UNIV CALIFORNIA
优先权: 2003
US
2 件公开
YKL-40 as a marker and prognostic indicator for cancers
US 7670599 B2
申请人: UNIV CALIFORNIA
优先权: 2005
US
2 件公开
第 1 / 3 页
上一页
下一页
药物
反馈